ποΈ
Archived grant β no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Influence of Caffeine on Melanoma
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Jan 2023Deadline 14 Jun 2025 β οΈ
NIHUS FederalResearch GrantFY20253'5'-cyclic ester of AMP3,5 cyclic AMP synthetaseActinic RaysAdenosine Cyclic 3',5'-MonophosphateAdenosine Cyclic MonophosphateAdenosine Cyclic Monophosphate-Dependent Protein KinasesAdenosine ReceptorsAdenosine TriphosphateAdenosine, cyclic 3',5'-(hydrogen phosphate)Adenyl CyclaseAdenylate CyclaseAdenylpyrophosphateAdenylyl CyclaseAffectAnimalsApoptosisApoptosis PathwayBinding ProteinsBioluminescenceBody TissuesCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCaffeineCalciumCas nuclease technologyCell BodyCell Communication and SignalingCell CycleCell Division CycleCell SignalingCellsCessation of lifeClinical TrialsClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCoffeeConsumptionCoupledCutaneous MelanomaCyclic AMPCyclic AMP-Dependent Protein KinasesCytoplasmDataDeathDifferentiated GeneDiseaseDisorderDoseDrugsELISAEnergy TransferEngineeringEnvironmental ExposureEnzyme-Linked Immunosorbent AssayEpidemiologic ResearchEpidemiologic StudiesEpidemiological StudiesEpidemiology ResearchExposure toFamilyFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFluorescent ProbesFutureG Protein-Complex ReceptorG Protein-Coupled Receptor GenesG alpha13 ProteinG(13) ProteinG-Protein Signaling PathwayG-Protein-Coupled ReceptorsG-ProteinsG13 G-ProteinG13 ProteinG13 Subunit G-ProteinGPCRGTP-Binding ProteinsGTP-Regulatory ProteinsGalpha13 ProteinGene TranscriptionGenetic TranscriptionGeographyGuanine Nucleotide Coupling ProteinGuanine Nucleotide Regulatory ProteinsHumanHydrogen OxideImmuneImmune mediated therapyImmune responseImmunesImmunoblottingImmunocompetentImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIn VitroIn complete remissionIncidenceIntracellular Communication and SignalingKnock-outKnockoutLigand Binding ProteinLigand Binding Protein GeneLigandsMITF proteinMalignant Cutaneous MelanomaMalignant MelanomaMalignant Melanoma of SkinMalignant Skin NeoplasmMediatingMedicationMelanomaMelanoma CellMelanoma SkinMiceMice MammalsMicrophthalmic-associated transcription factorMinorityModern ManModernizationMurineMusObservational epidemiologyOutcomeP1 PurinoceptorsPD-1 antibodyPD1 antibodyPKAPathway interactionsPatientsPersonsPharmaceutical PreparationsPhosphorylationPredispositionProgrammed Cell DeathProliferatingProtein BindingProtein FamilyProtein Kinase AProtein PhosphorylationProteinsPurinergic P1 ReceptorsRNA ExpressionReceptor InhibitionReceptor ProteinReceptor SignalingReporterResistanceResolutionResponse ElementsRiskRisk ReductionShort interfering RNASignal PathwaySignal TransductionSignal Transduction SystemsSignalingSignaling Pathway from G-Protein FamiliesSkinSkin CancerSmall Interfering RNASusceptibilitySystemTestingTherapeuticTissuesTranscriptionTransgenesUV lightUV radiationUV raysUltraviolet RaysWaterWestern BlottingWestern ImmunoblottingaPD-1aPD1adenosine 3'5' monophosphateantagonismantagonistanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1biological signal transductionbound proteincAMPcAMP-Dependent Protein Kinasescomplete responsedermal melanomadrug/agentdruggable targetenzyme linked immunoassayepidemiologic investigationepidemiology studyexperimentexperimental researchexperimental studyexperimentsflow cytophotometryhost responseimmune competentimmune drugsimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunoresponseimmunotherapeuticsimmunotherapy agentimprovedin vivoinsightknock-downknockdownmalignant skin tumormelanocytemelanoma cancer modelmelanoma modelmelanoma tumor modelmicrophthalmia-associated transcription factormouse modelmurine modelnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachoverexpressoverexpressionpathwaypharmacologicpre-clinicalpreclinicalprotein activationprotein blottingreceptorreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskresistantresolutionsresponserisk-reducingsexsiRNAstandard of caretargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttheoriestranscription factor Microphthalmiatransgenetumortumor growthultra violet lightultra violet radiationultra violet raysultraviolet lightultraviolet radiationΞ±PD-1Ξ±PD1
Applications closed.
Description preview
Abstract:
Melanoma is the fifth most common skin cancer; however, it is the most lethal. A minority of patients achieve a
durable complete response to current standard of care immune and targeted therapies. Clues to new
therapeutics may be found in understanding why melanoma incidence and outcomes differ significantly between
groups of people thatβ¦
π
Start 7-day free trial β $29.99/mo βFull details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link β plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more β with email alerts and pipeline tracking.
$29.99 / month
- πEmail alerts for new matching tenders
- ποΈTrack tenders in your pipeline
- π°Filter by contract value
- π₯Export results to CSV
- πSave searches with one click